Management of Diarrhea in Colon Cancer Patients

Initial Assessment and Management

The American Society of Clinical Oncology recommends starting loperamide immediately at 4 mg followed by 2 mg every 4 hours or after every unformed stool (maximum 16 mg/day) for mild to moderate diarrhea, and escalating rapidly to octreotide 100-150 μg subcutaneously three times daily if symptoms persist beyond 48 hours on loperamide 1, 2
Dietary changes should be initiated while starting pharmacologic therapy, including eliminating lactose-containing products, alcohol, spicy foods, coffee, and high-osmolar dietary supplements, as recommended by the European Society for Medical Oncology 2, 3
Patients should be encouraged to consume 8-10 large glasses of clear liquids daily to prevent dehydration, according to the National Comprehensive Cancer Network 4
Patients should record the number of stools and immediately report fever or dizziness upon standing, which are warning signs of life-threatening complications, as advised by the American Society of Clinical Oncology 1, 2

The American Society of Clinical Oncology recommends loperamide 4 mg initial dose, then 2 mg every 4 hours or after each unformed stool (maximum 16 mg/day) as first-line therapy for mild to moderate diarrhea 1, 2, 3
If diarrhea persists >24 hours, loperamide should be increased to 2 mg every 2 hours, and oral antibiotics (fluoroquinolone) should be added as prophylaxis for infection, as recommended by the American Society of Clinical Oncology 1, 2
For refractory diarrhea, octreotide 100-150 μg subcutaneously three times daily should be started, with dose escalation up to 500 μg three times daily or 25-50 μg/hour by continuous IV infusion if needed, as advised by the European Society for Medical Oncology 1, 3

The American Society of Clinical Oncology recommends recognizing early warning signs requiring aggressive intervention, including fever, dehydration, neutropenia, or blood in stool, which indicate complicated cases requiring immediate escalation 1
Immediate management should include starting octreotide 100-150 μg subcutaneously three times daily or IV (25-50 μg/hour) if dehydration is severe, as recommended by the American Society of Clinical Oncology 1
IV fluids should be initiated targeting urine output >0.5 mL/kg/hour and adequate central venous pressure, as advised by the European Society for Medical Oncology 3

For bile salt malabsorption, bile acid sequestrants (cholestyramine, colestipol, or colesevelam) should be added as adjuvant therapy, as recommended by the European Society for Medical Oncology 3, 4
For immunotherapy-induced diarrhea, symptomatic treatment with loperamide or racecadotril should be started for Grade 1, and budesonide 9 mg once daily should be added for Grade 2, as advised by the European Society for Medical Oncology 3, 5